8
+0 腒腚腛腅腃腉腓腑腇腎腋腈腄腌腔腟 +0 腒腚腛腅腃腉腓腑腇腎腋腈腄腌腔腟 腝腗腏腓 Selected Papers +,+臤臩膠膀膚膁腃 ,腺膸臌臥腆腁腍腁腊 : 膙膋膆膊膗膇膔腃膓腻腽膂腽腶膖膇腵腲腾臣膖膚膉臼膎腸腲膚膁腃 膌腴膙膚腀腗 膃膢腵腲腾膺膱至 / : ++2+,/,**- +0 膃膢腵腲腾膺膱腝腣膽腈膠膺腢膍膙腸膕膑膞膢 腡腩腫膝膪腢 2 腭腘膥腞腔腜膀膘腷膄腓腭腔腘腻膚膏腼腳膑腞腔腜臡腮腭腘+Lopinavirritonavir .* 膽腈腵臜膮 ,臌臥膣腡腌腑腬腵腲腾臣腶膖膇膦腢膽腈腢腌腩 腤臵膺膠膝腝腡腛腊腜腢臕-膇膔腃膓腻腽膂腽腶膖膇腡腌腑腬膑腵: dihydrofolate reductase 腢膟臎腡膾腕腬臖臆 .AIDS 膖膚膉臼腡腌腑腬 EPOCH 膺膠膽腈 /HIV, HCV 膰膓膼臻腡腕腬 PEG-IFNa,a 膖膈膊膖膚腢膛膳膺膠 0HIV 腜腌膼臻腡腌腑腬膸臅膐膄腹膚膅 膖腰 DNA 腢臐致腵腴膼 1HIV-+ 腜腌膼臻腡腌腑腬腰膃腱膏腺腲膄腶腲膚臓膇腻 2Swim up 腡腩腬 HIV 臰腯腊腘膽腈腕腘 臀腻膚膏腼腽膄腡膋膒膂膲腯腥腞腧腜腊腘腙腏腓腪 腡臦膂膲腌腩腤膱腝腢臹腠腟腡膾腔腜腹膒膚膄 腯腛腑腘腠腌腰膎膹膰臲腣臣腝膂膲腢臀臨腯臷腓腭 腘腢腝腫膨膥臻腌腩腤腄腣腢腦臀腓腖腜腊腘腙腊腘+Lopinavirritonavir 腖腜 ., 腞腂腝腗腙腕腐 膸腛腹膡腒腍腹臠臞膿膪臝臞腹腊腂膢腹膏臃膻膤膊膆臗膯腊腐腦膜膨膪腥腶 臤臩膠膀膚膁腃腵腲腾臵臖臆膴膀膚膁腃 膫腵膟膠Lopinavirritonavir LPVrtv腢臜膮腯HIV 膺膠膲腝腉腬 naı ¨ve 臍腞腗腭膝腢臟 HIV 膺膠 腝腳腲膗腽膺腡臸腔腜腊腬 salvage 臍腞腡腑腜 ret- rospective 腡臕腔腘臒膮., 腎膷腔腘臜膮腣 .2 腁膫腢腳腲膗腽腔腘Naı ¨ve 臍腣 3 膺腞CD. 膵腔膖膚膉臅 CD ./* mm - HIV-RNA VL-+*,*** copiesml腟膾 AIDS 腝腉腚腘Intent to treat- ment ITT腡腜 /* copiesml 膦膤 01.** copiesml 2-腅腁 On treatment OT腡腜 /* copiesml 膦膤 2*.** copiesml 膦膤 +**腝腉腚腘3 膾腰 . 腅膧腔 膔腖膧, 膉膍腴臎臟臮臊腧腪腭腘highly active antiretroviral therapy HAARTVL .** copiesml salvage 臍腞腔腘Salvage 臍腣 -- 腝臵 膺臀腞腔腜膸臮臏臃臺臢腠腡NNRTINNRTI 膿臯臍腡腑腘NNRTI ,, 腢臵膺腞CD. ,-* mm - VL 1,-** copies ml 腉腚腘ITT 腡腜 /* copiesml 膦膤 /*.** copiesml 03腅腁 OT 腡腜 /* copies ml 膦膤 /1.** copies ml 膦膤 13腝腉腚腘1 腰腭膾腰 / 膂膘膷腝腉腚腘NNRTI 膿臯++ 腢臵膺腞腮CD. 2/mm - VL ,,*,*** copiesml 腝腉腚腘++ 膾腰 / AIDS 腝腉腚腘ITT 腡腜 /* copies ml 膦膤 ,/.** copiesml 膦膤 /*腅腁 OT 腡腜 /* copiesml 膦膤 /*.** copiesml 膦膤 +**腝腉腚腘++ 膾腰 0 腰腭 腞腠腫, AIDS , 臶臚腰腭 , 腝腉腚 腀腄+LPVrtv naı ¨ve 腞腞腨腡 salvage 腝腨臜腠 自腝腉腚腘腔腍腔臑腡膾腔腜膂膘膷腢膹腅膧腔 膔腖膧膬腫腞腠腚腘腢腹膒膚膄 ; 腝腣LPVrtv 膈膾腕腬臧臛腢腫臭腵膮自腝腉腬腔腍腔LPVrtv 腯腨腚 腜腔腜腨 NNRTI 膳臀腎腉腬腞臵臜膮腨臙腪腭腜腔腥 腋腒腞腎腪腍腡腠腚腘腓腪腠腬腑膮膐膴腝腉腬臁膶腚 : 膥臄 腄腈++-2011 腺膚臈臋臌臥 -+2,, 腺膸臌臥膣膽腜腌Fax : *--2,.+//, ,**- . +3 膃腀膕 ,**- The Japanese Society for AIDS Research The Journal of AIDS Research .2 ++2

Selected Papers · 2009-01-13 · .K AIDS ! ˝ "#5OPQEPOCH ˝ / ˇW˜ /K HIV, HCV a% bc5&^QPEG-IFNa,a > ˝d ˝ / ... ,**- The Japanese Society for AIDS Research The Journal of AIDS

Embed Size (px)

Citation preview

� +0��������� ����� +0��������� ����

���� Selected Papers

� � �+�� � � �,�

+� ��������,����� ��

����� : ������ ������������� ��� !��"#� $%��&'�� �( �

�����)*+ / : ++2�+,/� ,**-

� +0,�����)*-.���)/0�%123456789/ 2:�;�<=:�>?@�ABCD<� ��?=�EFG2>?@HI<=J

+K Lopinavir�ritonavirL� .*�/���MN,K ��5OPQ��� ����R/���O6ST��/��5UV@/W�-K ������������5OPQ X!�Y" :

dihydrofolate reductase/Z#[$\5]^Q_`.K AIDS !��"#5OPQ EPOCH��/���W�/K HIV, HCV a%bc5&^Q PEG-IFNa,a>�d��/���0K HIVe'(bc5OPQ)�a*fg+hCij�kDNA/lm�,-1K HIV-+e'(bc5OPQknoEp�C��a+./2K q0 Swim up�56QHIV1r�[s�V=�( �/��23

4t�EF�C55678su>v@V=wx� Dy5z9;78O6S*:-/{;|}5]<?@i~CsUP=J |O+=>��.� -78/t�s�?D<=/-�@� :cO6SAB/�tD�@V=wV=J

+� Lopinavir�ritonavir�� .,������ �C�D� �EFG[� 4E��� HI��� EJK[�L�M�� �ENO[� ��MP� ��V��� Q�RT��S�� ��T� ���� IUV�����������T��_`�5���W�>X�� Lopinavir�ritonavir �LPV�rtv� /MNs� �

HIV��;Y,-�Q naı̈ve�>�<8Z/�HIV��-G���)�5�[?@VQ salvage�>5\P@ ret-

rospective5W�?=J��N� .,�;�]?=J MN. .2^W/G���--_,?=J Naı̈ve�. 3�J T�Z/`  CD.a��"gb �CD .� . /* �mm- -+¡cHIV-RNA- �VL� .-+*,*** copies�ml� d� AIDS-�¢=J Intent to treat-

ment �ITT� 5@ /* copies�mlef 01� �.** copies�mlef 2-��� On treatment �OT� 5@ /* copies�mlef 2*��.** copies�mlef +**�� -�¢=J 3�+ .�5gh�ijh� ,�5�k,\�£¤(;lvy<=J Z highly

active antiretroviral therapy �HAART� +5 VL; .**

copies�ml84s salvage�>?=J Salvage�. --�-T�m>?@kf£¥¦n§Y"o¨ �NNRTI�eL��>NNRTI©L��5\P=J NNRTIeL�� �,,��/T�Z.� CD.. ,-*�mm-� VL. 1,-** copies�ml-�¢=J ITT5@ /* copies�mlef /*� �.** copies�mlef 03��� OT5@ /* copies�mlef /1� �.** copies�ml

ef 13�� -�¢=J 1�/+p�+ /�.7qr/s9-�¢=J NNRTI©L�� �++�� /T�Zc.� CD.

. 2/�mm-- VL. ,,*,*** copies�ml-�¢=J ++�+ /

�; AIDS-�¢=J ITT5@ /* copies �mlef ,/��.** copies�mlef /*��� OT5@ /* copies�mlef /*��.** copies�mlef +**�� -�¢=J ++�+ 0�;+p>|7� tª� ,�� AIDS« ,�� ¬­+p ,�-�¢=J �6 +���u� LPV�rtv. naı̈ve�>>®5 salvage�-®vM| X-�¢=J ?¯?°w5]?@7qr/±x>gh�ijh;;�>|¢=J

z9/i~C ; ²y-.� LPV�rtv.� T��[�5&^Q³´/z7µ� X-�QJ ?¯?� LPV�rtvs®¢@?@®NNRTIL�m;�Q>T�MN®¶y<@?u·¸>;{y¯5|¢=J Dy|Q| ;}~-�QJ

�c<�� : �� � �¹++-�2011 �����º� � -�+2�,, ���� ��e'(»�Fax : *-�-2,.�+//,

,**-� .¼ +3� �

�,**- The Japanese Society for AIDS Research The Journal of AIDS Research

� .2 �++2

,� ��������� ��������������������� !�"#����� ����� ���� ������ ����� � ���HAART��������� ��� PCP� �������� � PCP��!�"��#$%�&'()(*+,�-���.#/01 PCP��2 #$�3*(4561�.�78+,�9:� +32/;,**,� 0<�4.� PCP5�2 ���=>1�? +/.� ��� +.,�� @� +,��� +1-�� �,-�� +,�� --�� -�ABC� .� ��D�E� ?.*.. �,+;01� F� ��D� CD.?�E -+.3 �*;--3��ml.G'1, STHI.��AJK01 +./�! 2.��/1.3�� L"M#�� ��A�N0(*1, OPQRSP.?� T>5$U0(VW*%��%XY��&Z[\]^'� ^_(�� (^'�M)� `�W"M#%*a+bL,-.G+5cde>1, OPQRSP�.�f/.?0g ,,�� 1g +2�.G'1��20� atovaquone34.?0g ,-��1g ,��"M#�(!h .�5W'(*1, Atovaquone?� g:.?OPQRSPf/�i �"M#%$U VW*T5je� k�je!)�4.�PCP� G+*? STHI\OPQRSP567+L"M#.l8.)W*9H��N:50(0#.G'1, ;m.?� PCPn<�o���+p=L +1� �3.2�� .G'1,+33*;+33.�� /�q� PCPA��01 -2�!.?� ,0

�L�� -��3�>�\?�H@rs�� p=0(*

1,tA� +331��u�>�A��0HAARTB/LXC.G'1 0+�.?� Dvwq3.�p=L /��x.G'1, yzE�!� /0�! -,�L CD. ,**�ml�F�{|�� G}HIL~J0(! � PCP����G}HI!�"HAART�� � �������s��H�%K)a��0()(*+T5L�ej5W'1, �L ,�

�M���P� ; N -� PCP��:50( atovaquoneL0g.G+T5L�=>(*1, O�P��|'(*�+����50(%� QxL,-5W'(T��,

-� �$%&'()(�������*+,-./ :

dihydrofolate reductase�01234�5678]��+� �R�S+� !�TU,� V���-� KW��-� ��XY.� �>��+, ,

+� Z�K������ [\����¡PQ¢ ��]^� ,� _`a� �b£3�� -� Z��cZ� ���� .� _�3��� � PCP���50(� sulphamethoxazole �SMX� -trimethoprim �TMP� Ld#=>+,¤¥?� �¦¢§¨©ª©���� �Pc� �!�+ SMX�e «f.G+dihydropteroate synthaseg¬�­R®¯�°5 Pc�����g:(��±.�A>���!*(�L01, �-?� TMP� e « f . G + dihydrofolate reductase

�DHFR� g¬�­R®¯�°�015 Pc�����hi�±.�A²j0� PCP���hi�³F´k(+,

9 + LPV�rtv�9: �.2µ��

��¶��l�AIDS�

��mCD. �average��CD. range�VL �median�

��n��E:Il��E·#µl�

ITT

OTCD.lF¸

!��ln¹!�"M# �ºo�AIDS±./*pq .**pq

»-���3�3�

/*�mm-

�.�+./�-+*,*** c�ml

01�2*�

2-�+**�

+2*�mm-

.�*�,� �,��+� �MAC�

Salvage

NNRTI

p·#�,,�-�

,-*�mm-

�2�.21�1,-** c�ml

NRTI��n : .I : ,00µPI��n : ,./I : +12µ

/*�/1�

03�13�

+11�mm-

1�/�*�+� �NHL�

NNRTI

¼·#�++�/�

2/�mm-

�,�/+-�,,*,*** c�ml

NRTI��n : ../I : ,,0µNNRTI��n : +.-I : .+µPI��n : ,.3I : +.2µ

,/�/*�

/*�+**�

,+-�mm-

0�,�,� �+��,� �PCP�PML�

The Journal of AIDS Research Vol. / No. , ,**-

� .3 �++3

���� ���� +33.� .��� ,**,� /���� � PCP -.�� ����� : HIV���,.�� HIV��� +*�� ��� ������� �BALF� ����� � PCR���!"DHFR�#��� � $���%&'()����*� "� �+,���-� �� . "� / Pc0��,1�23��� "� 1�45�6 ��7� +*�89�� ":;< !,=">#?@ABC� DDHFR�#,�+D,E$%�F& ���G5� DHFR�#,'()��+ �A01V, C+00Y� � ,

� �/.3�� �#?�� �' -� H � ,�D: PCP,1�45,�6�I@ABH!�� �� (�#�JK�'()��+�)@BC$���,�L� ,MN �-+, : TOC,

/.* : TOC� #?�� *+P� Q,RSTUP� 0UP�-.-VWX'Y/�JC"0Z[A"C�� TMP1%�E�\�DHFR,'()��+,2]D� ^_ Pc�JC"#?@A�DHFR,'()��+2]�3` �>� a4\��+2]�I@ABH!��

�G5� Pc�JK�DHFR�#,b6c7d�#?�>�^_� #?@A�'()��+ �A01V, C+00Y� �� TMP

1%�E�\�e8%�fg BH!��

h9,ijkl ; mn@, Pc, STo71%b6c�E\�a$,0Z��� p�q:��rs��� �tu STo7;<v=��^_,1%�+>IwH�HxyHBx^z,>?�{@\��

.� AIDS��������� EPOCH��������|ABC� :DE� F}GH� ^I~�� ����� JKL�� ��*�� M�*N� �O�PQ��R������ST� AIDSoU�%Xk���� AIDS��D+B�V�T1�>�!"CBC� ��W�� EPOCH�� �Etoposide, Prednisolone, Vincristine, Cyclophosphamide,

� , ��R��JK����oU�X�0,D? �+32/�,**,� 0�X�

!��Y +/.Z +1-�� �,_�� +,Z� -_�� -Z����

�[�%\ ]� .*.. �,+�01� ��^% +.,Z� �% +,Z

PCP���_��` +*0Z �02.2��

PCP AIDS��D`a +,3Z �2-.2��

`a  CD.Y ]� -+.3 �*�--3��ml

�b �¡¢Y��- +*+�� cdA�;<£e 3/�¤f 2+�� gh -,�

STo71��¥¦+./��§,y¨ 2.� �/1.3�� >i©j1��ª�

1�,kl �¡¢Y�

STo7mn +/+�� STo7op +/�«k¬(­kop 2*�� «k¬(­k<q .*�'l®ik ,3�¯XV°k±²Xk³V�´k +,�³¯µk±²Xk³V�´k 0�

r¶·¸ +.1�� ¹s ,0�¹s,y¨ PCP���:, +1� �!t, 3.2��

HAART���;z,�L

+32/�+33.���� � /,Z,`a -�,23+32/�+33.���� � /,Z,`a -�,23`a -�8m�¹s -1Z �1+.,��`a -�uv .Z �1.1�� G ++Z �,+.,��

+331�8º��� HAART�wq � 0+Z,23+331�8º��� HAART�wq � 0+Z,23�,**,� 0�X»¼�

uv /0Z �3+.2��¹s /Z �2.,��

S Oka and A Ajisawa : Clinical Medicine Selected Papers

� /* �+,*

Doxorubicin���� ��������� �� ������� EPOCH������� AIDS���� !"# /� $%&'( di#use large B cell lymphoma� ��%��)�*+��,��-./0 1 .�23�� /4�5� CR,�� PR+�� PD,�6 ,�� PD4��37� 4� +89:;8<=>6�CDE�� 0?@A��B�(CD6� salvage����EPOCH� +?@A��B�(CD6EF� 4� -8 0/

GH�69:;8IJ S/6� EPOCH�� +?@A��B�(Grade.�KL�MNOP��QRST�UV�� 5W� CDE���XYB��KL�MHIVZ4�

[��EF��� \]���Grade-^.�KL�M�_`�ab�����cRdeSQATf� LPV�rtv�gh6%� ,4�68QRST�iV��� V'j�4�68� LPV�rtv�fklm]��2� Vincristine�n5op�=q��V�rstuj'�� V�374� .8�vw�� ,?@Ax��y� LPV�rtv�Nelfinavir�z{�� |}~�������-.�0 AIDS���� !"#��B�����vw��8%��b��� ��� EPOCH��8\]�(����6�����6 �tuj'���b�� HAART$highly active anti-retroviral therapy� ���2,�8N

� . ���� EPOCH������� HIV�� !"#� /4�

����

��stage

PS

LDH�CD.�Viral load

HAART �� \]� D/

.3

H����

PS�*

,02

+//

.**��d.T�ddI�EFV�NFV

CDE�RT$0�@T�EPOCH

KL�M PD�

/+

H� ��

PS�*

-0,

+23

2-*-TC�d.T�NFV

EPOCH

$0�@T�RT.*Gy

KL�M PR

0/

H�J�

����$HIVZ4�-*,

+-

+/*�ddI�EFV�IDV�LPV�r

EPOCH

CDE

$+�@T�

KL�MQRST

PD�

-1

H����

PS�*

+1/

,12

.**��

-TC�d.T�LPV� �r

-TC�d.T�NFV

EPOCH

0�@TKL�MQRST

CR

0-

H���

PS�*

+0/

--

,2�-TC�d.T�NFV

EPOCH

0�@TKL�M CR

 -�x8 EBVassociated DLBCL

� - ¡ ¢J£4��i¤� DHFR�¥�¦§¨©zª ST�����«¬

4�DHFR�¥ $­®¯� ?e@!�

��«¬°±²� : ³G,**CT³T/-3GT³¦§¨©²� : ³ 01Ala³ +00Cys³

zª¯�­®¯

-°±²� : ³G,** TT³T/-3GT³¦§¨©²� : ³ 01Val³ +00Cys³

+*�* «´

-,

$µ� BALF�°±²� : ³G,**CT³T/-3 AT³¦§¨©²� : ³ 01Ala³ +00Tyr³

0�. «´

-,

$,�x BALF�°±²� : ³G,**CT³T/-3 AT³¦§¨©²� : ³ 01Ala³ +00Tyr³

+*�*

��� Pc�i%�_`j'�°±¶·¦§¨©²��i¤�¸¹�º»6¼���

The Journal of AIDS Research Vol. / No. , ,**-

$ /+ �+,+

��������������� ��� ��������

������ ; � ������������� �!���� EPOCH�������"�#�$�%����� ��&"� �'$%(�&"��� ����)*modification���%$����

/� HIV, HCV��������� PEG-IFNa,a ����������+�,+� ����,� � !-+� "#$%+� ."�&%+�'"/0+� �(10+� )"*2,� �"+�%+� 34�56+� 78!,+� -9.�+� /):0+� ;<1-� <2=+�(34+

+> / 5?�@�AB������CDE6@�AB,> 7F8G?G9:;<HI=>J9 -> ?@?KAK8GI=BC?GLDEM F@�AB�GHH�HIV, HCVNIOJ<PK��� PEG-IFNa,a� QR ��I����LS��;M��TN$�LO�M F@�ABGHH� 0P�HIV, HCVNIOJ<PK��Q�$� PEG-IFNa,a� QR ��I����U�VW�RS�XY�Z� LS��L[TQ�\�ZUV$� WX�ZY �Z��PK�]��Q�$� PEG-IFNa,a +2* mg�ml[^�\�] +_`�� QR �" 2**mg�� ,&��ab^_$� ,.]cI�d�Se�L[TQ�`f$� LS&��#a8 .2]c�Db�$� ,.]cd�LS"� ,.]^_d�HCV-

RNA�g�&����$� L[TQ��hZ%PK�eF?f�gh&^_ii�jk����lm��nN"iijo�$�LkeM�Olm�n� op�p�Z���Mq�rH$Z PEG-IFNa,a� QR ��I����Es$�0q��%OJ< A&� qr�so��" .��HAART

trH& +��tuuvvwwxy[A xNRTIy ,z� +

��{��&�z� Esc CD."H{|& -0-�ml x,0*�//1y &�h� .�� genotype+b& +a� -a�| +�&�HCV-RNA�"H{|& 2+/KIU x+.*�2/*}'y &�h� -�� .2]�}~$� +�" ,.]cd&HCV-RNA

���~'}~� ,�� /]�� +,]&Hm$� .2]iijo&�h -�" +.]D xgenotype +ay� +0]Dxgenotype +by� ,*]D xgenotype +by &HCV-RNA���&g��$� +,]D&�u���B�o�NI��z^_�Hm$ +�" xgenotype -ay� Esd .2]cd&"� HCV-RNA���&g��$Z�� ���� +***

��������q� /�� . g}'�Hb��^� ,��

O���� x+*��ml��y � ,������� ������NI� �u���B�o�NI�(������� x� +yLk�M����� $�����6f|"����������� ��E�a�����d%�&��

������ ; PEG-IFNa,a� QR �����"� q��"�����HCV-RNA�\ genotype +b&%LS����������� $�$=O���%������ PEG-IFNa,a�^_�����d���TN��&��

0� HIV-+��������������� !"�#�$ DNA�%&'()���,+� d�+�%+�����+��"��+��3��+�H34�,� ���.+, ,

+> 7F8G?KGCD���?�CD@�ABI=q� � ,> 7F8G?KGCD�:;<HI=¡�¢KL£�M �p����uvvwwxy[z xNsRTIsy �����¤5�"�  ���� �DNA xmtDNAy �N�y[�U_$Z������Z��LDEM HIV-+I=qPK�¥�O¦t� xPBMCsy HmtDNA�acE���$� HAART�_�¡¢������%�� mtDNA������6£�§�B¨¤%��z��TN��LO�M -*0� PBMCs¥�¦s x.0��PK� �� ,3��§©�yH�mtDNA�� bactin� Real-time PCR&��$� mtDNA��t¨©ª���ª&«$� �����U��L{�\�Z¬«GE�¬­$�Lke����M ����PK���Z� mtDNA"§©��ª­��$Z� xp®*.***0y� ¯� (��" CD.®� T�¯��°�gU��$� HIV-RNA��±�gU��$ x� ,A�� By� ��°M² xn®--y &"� ��Es +***�}'&� mtDNA"L �³±��������� NsRTIs�´�²���³Z¬­$nN� AZT�-TC xn®2y ¯" d.T�-TC xn®+,y ��´°&"mtDNA"³±$Z� x� ,Cy� ����µN���HIV-+I=¶²�mtDNA����~� ����z_·$Z�jo������� =O� AZT�ddC xn®/y ��´°&"mtDNA"L ���$Z� x� ,y� ���¤�$Z"� ddC�a%µ�mtDNAN�y[Se�� ¸°&����mtDNA��_·�¹¶$Z�jo������� ��� ,°�c&� ��Es +ºd�O·GE!¸�BA�L �»"����h� ¯� ¹��º»¼B� ¥�¼ak[�L{� ��OH�u|�mtDNA���c�%U������h� ¥�O¦t�

S Oka and A Ajisawa : Clinical Medicine Selected Papers

x /, y+,,

�mtDNA����� ���� ��������������������

� �!"#$ ; NRTI�%&'$!#()*+,-./0/HAART�12&�� �3��456789*:;.�5�&-<�=>?@��'$!#()*A��� �����BC&D��EFAG&D�-H.���

1� HIV-+��������� ������������IJK� LMNO� PQRS� <TUVWXYZ[\]^_#`8abcdef�gh�ijklm

2� �� Swim up���HIV���� !"#$%&�'()*+nopq+� rstu,� v�w-� xyz{.� |}~V.� ����/� �Q��/� ����0� ����0� ���V.

+� ��YZ=�h� ,� ���������� -� ���h�� ¡YZ¢£¤h� .� ¥¦��¢£¤h� /� ���

, +�, HCV-VL of None-Genotype +b Treated with PEG-IFNa,a§RBV

, +�+ HCV-VL of Genotype +b Treated with PEG-IFNa,a§RBV

The Journal of AIDS Research Vol. / No. , ,**-

¨ /- ©+,-

�������� 0 ���������� ����� Swim up����HIV��������HIV-RNA, proviral DNA�� !� "#$��%&!'(�)� *+HIV���,-.�/0!� 1234�56/0�*��789:;<�$=!>?@ABCDECF�&G����HIEJKCFLM�%&!'(N�OP�QR��� S�T���� ���� -%U�����VG>WX informed consent�Y'Z� �-[���HIV

� �\]!>"#$��%&!'( ^_ -`�OP abc,� /,d�*�+9:;<�$=!*��

�LM�%&!'( -��e,HIV��+f�!�#gh'( ,,d+"#$�i%%U�jkgh'( �� Swim up

����HIV RNA, proviral DNAl�m7�� !'�-�no,p'( +,� ^q�;r� 0d�s��� 0d`�tu�i%!� +*�+vw!� -�+x�!'( i%ysz{|-l�78HIV���}�~'( �� 2/��HIVs�s���LM�������-� .***��ml����� -*�� ������ +*�,� PercollZ�no�-� /,**��ml� ���� /2�,� swim upZ�no�-� ,**��ml� ���� +**�,�~'( IFN�E��EC� �&���-���}��+]��h'(

� , �� HIV-+���r����q������C�E� DNA�� CD.s T���c'� HIV-RNA

����  ^Az{ B`� z{ NsRTI�¡�,¢£'���C�E� DNA��¤¥�¦§ ^Cz{ D`Az{ B : CD.s T���z{� HIV-RNA��� Nh¨h .0�� ./z{ --�,©ªgh>G'(i«�n¬­«�®¯(Cz{ D : °±� ,**²³��´µ~'� ¶·�®!� ¸±�� ¹�º»�!'�¼����C�E� DNA��®¯(a : Spearman’s ranks test, b : Wilcoxon signed ranks test, c : paired t-test

S Oka and A Ajisawa : Clinical Medicine Selected Papers

^ /. `+,.

���� �� Swim up�� ,�� ����������������� � ! "#$%&'�()*+,-./�01�2�34�56789! ,�� ��:�;<%�=! >?@AB�CDE=�� HIV� 4E/�6�FG9/�HI�JK9�2�LM�N��:O���,-./E������PIQRJ�! ST0/�UV0/�CD+LM�WXE=Y�� HIV�CZ[\E IFN]^_`^abc�deLMR/�@fgh7ijkl�CD�=��

mn@opaq ; �� Swim up�Edr��! HIVsQ

34@/t��ST0/�uvE=���������� 9w9()*+ ���,-./E ,�� �xye���iz{��! �|}cH~Ed��e�+��R>?�O�jk�CDE=��

�?�2�@���i�! �8@HIV�c�@q���%�~�9��! ��}�����E=���r��� �@e+�����O��� +0����#����n! ����x� ¡l��

� - ST0/@¢£qo<$

The Journal of AIDS Research Vol. / No. , ,**-

¤ // ¥+,/